Clinical Trial

Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer

Study acronym: ARTHOUSE
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study seeks to study the population of HPV-related oropharynx cancer patients that appear to be at highest risk for treatment failure with loco-regional failure and distant metastases including cT4 or cN3. The study team aims to determine if it is feasible to use multi-modality imaging (both DCE MRI and FDG-PET) to optimize the radiation boost in high risk p16+ OPSCC with similar or decreased toxicity compared to historic standard therapy.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-01-22; most recent amendment 2026-05-15.
Status change: Recruiting → Active, Not Recruiting 2025-05-12
Trial Details
NCT Number NCT06234748
Lead Sponsor University of Michigan Rogel Cancer Center
Conditions Oropharynx Cancer, HPV-Related Carcinoma
Enrollment 19 participants
Start Date 2023-12-20
Primary Completion 2028-07 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2026-05-18